A number of the reported therapeutic strategies have designated insulin sensitizers, lipid-lowering agents, antioxidants, and cytoprotective agents as therapeutic measures against multifaceted NAFLD pathways. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.